Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Medicine Co., Ltd.
和譽醫藥有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT

Abbisko Therapeutics Presents Preclinical Findings on Novel Selective CDK4 Inhibitor ABSK192 in Single-Agent and Combination Studies at 2026 ENA

Abbisko Medicine Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that preclinical findings for ABSK192, a novel selective CDK4 inhibitor independently developed by Abbisko Therapeutics, were presented in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics of 2026 ("**2026 ENA**"). The study was selected for the Late-Breaking Abstracts ("**LBA**") program. Dr. Nannan Zhang, Senior Director of Translational Medicine and Biomarker Research at Abbisko Therapeutics, presented the findings, highlighting the single-agent activity and broad combination potential of ABSK192 in HR+/HER2- breast cancer models.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK192 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Medicine Co., Ltd.
Dr. Xu Yao-Chang
Chairman

Shanghai, 19 November, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Presents Preclinical Findings on Novel Selective CDK4 Inhibitor ABSK192 in Single-Agent and Combination Studies at 2026 ENA

On 19 November, 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that preclinical findings for ABSK192, a novel selective CDK4 inhibitor independently developed by Abbisko Therapeutics, were presented in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics of 2026 ("**2026 ENA**"). The study was selected for the Late-Breaking Abstracts ("**LBA**") program. Dr. Nannan Zhang, Senior Director of Translational Medicine and Biomarker Research at Abbisko Therapeutics, presented the findings, highlighting **the single-agent activity and broad combination potential of ABSK192 in HR+/HER2- breast cancer models**.

CDK4 is a key regulator of the G1/S transition in the cell cycle and an important therapeutic target in HR+/HER2- breast cancer. Although approved CDK4/6 inhibitors have demonstrated clinical benefit, CDK6 inhibition is often associated with hematologic toxicities, which may compromise treatment tolerability and limit sustained CDK4 target coverage. Furthermore, the diverse treatment landscape of HR+/HER2- breast cancer highlights the need for novel selective CDK4 inhibitors and further exploration of their combination potential with existing therapies, particularly endocrine therapies.

The study results demonstrated that **ABSK192 exhibits potent CDK4 inhibitory activity with greater than 70-fold selectivity over CDK6**. Across HR+/HER2- breast cancer cell models, ABSK192 showed robust antiproliferative activity regardless of PIK3CA mutation status and induced pronounced G1 cell-cycle arrest. In vivo studies further demonstrated robust antitumor activity with ABSK192 as a single agent.

Furthermore, **ABSK192 demonstrated broad synergistic potential in combination studies**. *In vitro*, ABSK192 showed synergistic activity across multiple HR+/HER2- breast cancer cell models when combined with the endocrine therapies fulvestrant and imlunestrant, the PI3K inhibitors GDC-0077 and RLY-2608, and the CDK2 inhibitor PF-07104091. *In vivo* studies further showed that combinations of ABSK192 with fulvestrant, imlunestrant, or GDC-0077 enhanced antitumor efficacy, achieving tumor volume regression.

These findings further support the development potential of ABSK192 as a novel selective CDK4 inhibitor and provide a preclinical rationale for exploring its use as a single agent and in combination regimens for HR+/HER2- breast cancer. Abbisko Therapeutics will continue advancing the development of ABSK192 and exploring its differentiated therapeutic potential, with the goal of bringing innovative treatment options to patients.

About ABSK192

ABSK192 is a novel, potent, highly selective, and brain-penetrant small-molecule CDK4 inhibitor independently developed by Abbisko Therapeutics. It is designed to selectively inhibit CDK4 while sparing CDK6, with the potential to improve treatment tolerability. ABSK192 has demonstrated promising single-agent activity and broad combination potential in preclinical studies and is currently in IND-enabling development.

About Abbisko Therapeutics

Founded in 2016, Abbisko Therapeutics is a pharmaceutical company committed to the research, discovery, and development of innovative and differentiated medicines designed to address unmet medical needs in China and globally.

Adhering to international concepts and standards for drug development, Abbisko Therapeutics primarily centers on small molecules, emphasizing precision oncology and immuno-oncology, with a growing expansion into both non-oncology therapeutic areas and other modalities. Its self-developed Class 1 innovative drug, pimicotinib, has received approval from the China NMPA and the US FDA, while dozens of other candidates are currently in clinical development stages.

Abbisko Therapeutics is committed to creating first-in-class and best-in-class innovative drugs. Through an unwavering pursuit of scientific innovation, the company strives to provide transformative therapies with breakthrough efficacy for patients worldwide.

For more information, please visit www.abbisko.com.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.